FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129186502> ?p ?o ?g. }

• W2129186502 endingPage "1445" @default.
• W2129186502 startingPage "1444" @default.
• W2129186502 abstract "We read with interest the study by Nix et al. [1.Nix P. Lind M. Greenman J. et al.Expression of Cox-2 protein in radioresistant laryngeal cancer.Ann Oncol. 2004; 15: 797-801Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar], in which they attempted to investigate the possible relationship between cox-2 protein expression and treatment failure in early-stage laryngeal cancer treated with radiotherapy. They found that overexpression was significantly associated with radio-resistant tumors (P=0.004) and suggested that cox-2 inhibitors might have a role in enhancing the effects of radiotherapy. Two important and recently published randomized trials clearly showed that in patients with operable high-risk head and neck cancer, concurrent use of radiotherapy and chemotherapy is superior to radiotherapy alone with regard to disease-free survival and/or overall survival [2.Cooper J.S. Pajak T.F. Forastiere A.A. et al.Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.N Engl J Med. 2004; 350: 1937-1944Crossref PubMed Scopus (2329) Google Scholar, 3.Bernier J. Domenge C. Ozsahin M. et al.Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.N Engl J Med. 2004; 350: 1945-1952Crossref PubMed Scopus (2251) Google Scholar]. In these trials, in the concurrent arm, radiotherapy was combined with cisplatin, which is the most common and effective radiosensitizer of all chemotherapeutic agents. A recent study reported that the cox-2 inhibitor JTE-522–cisplatin combination elicited a synergistic and additive antitumor effect in different gastric cancer lines [4.Sugiura T. Saikawa Y. Kubota T. et al.Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo.In Vivo. 2003; 17: 229-233PubMed Google Scholar]. A study by Peng et al. [5.Peng J.P. Liu L.T. Chang H.C. Hung W.C. Enhancement of chemotherapeutic drug-induced apoptosis by a cyclooxygenase-2 inhibitor in hypopharyngeal carcinoma cells.Cancer Lett. 2003; 201: 157-163Crossref PubMed Scopus (14) Google Scholar] also demonstrated that the cox-2 inhibitor NS398 potently augmented chemotherapeutic drug-induced apoptosis in hypopharyngeal cancer. NS398 also radiosensitizes head and neck squamous cell carcinoma cell lines, possibly by inhibiting radiation-induced expression of cox-2 [6.Amirghahari N. Harrison L. Smith M. et al.NS 398 radiosensitizes an HNSCC cell line by possibly inhibiting radiation-induced expression of COX-2.Int J Radiat Oncol Biol Phys. 2003; 57: 1405-1412Abstract Full Text Full Text PDF PubMed Scopus (18) Google Scholar]. These preclinical and clinical data suggest that the cox-2 inhibitor–cisplatin combination may be more useful than cisplatin alone as a radiosensitizer in the treatment of head and neck cancer that overexpresses cox-2 protein. We read with interest the study by Nix et al. [1.Nix P. Lind M. Greenman J. et al.Expression of Cox-2 protein in radioresistant laryngeal cancer.Ann Oncol. 2004; 15: 797-801Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar], in which they attempted to investigate the possible relationship between cox-2 protein expression and treatment failure in early-stage laryngeal cancer treated with radiotherapy. They found that overexpression was significantly associated with radio-resistant tumors (P=0.004) and suggested that cox-2 inhibitors might have a role in enhancing the effects of radiotherapy. Two important and recently published randomized trials clearly showed that in patients with operable high-risk head and neck cancer, concurrent use of radiotherapy and chemotherapy is superior to radiotherapy alone with regard to disease-free survival and/or overall survival [2.Cooper J.S. Pajak T.F. Forastiere A.A. et al.Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.N Engl J Med. 2004; 350: 1937-1944Crossref PubMed Scopus (2329) Google Scholar, 3.Bernier J. Domenge C. Ozsahin M. et al.Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.N Engl J Med. 2004; 350: 1945-1952Crossref PubMed Scopus (2251) Google Scholar]. In these trials, in the concurrent arm, radiotherapy was combined with cisplatin, which is the most common and effective radiosensitizer of all chemotherapeutic agents. A recent study reported that the cox-2 inhibitor JTE-522–cisplatin combination elicited a synergistic and additive antitumor effect in different gastric cancer lines [4.Sugiura T. Saikawa Y. Kubota T. et al.Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo.In Vivo. 2003; 17: 229-233PubMed Google Scholar]. A study by Peng et al. [5.Peng J.P. Liu L.T. Chang H.C. Hung W.C. Enhancement of chemotherapeutic drug-induced apoptosis by a cyclooxygenase-2 inhibitor in hypopharyngeal carcinoma cells.Cancer Lett. 2003; 201: 157-163Crossref PubMed Scopus (14) Google Scholar] also demonstrated that the cox-2 inhibitor NS398 potently augmented chemotherapeutic drug-induced apoptosis in hypopharyngeal cancer. NS398 also radiosensitizes head and neck squamous cell carcinoma cell lines, possibly by inhibiting radiation-induced expression of cox-2 [6.Amirghahari N. Harrison L. Smith M. et al.NS 398 radiosensitizes an HNSCC cell line by possibly inhibiting radiation-induced expression of COX-2.Int J Radiat Oncol Biol Phys. 2003; 57: 1405-1412Abstract Full Text Full Text PDF PubMed Scopus (18) Google Scholar]. These preclinical and clinical data suggest that the cox-2 inhibitor–cisplatin combination may be more useful than cisplatin alone as a radiosensitizer in the treatment of head and neck cancer that overexpresses cox-2 protein." @default.
• W2129186502 created "2016-06-24" @default.
• W2129186502 creator A5014590544 @default.
• W2129186502 creator A5039840531 @default.
• W2129186502 creator A5089639776 @default.
• W2129186502 creator A5090532877 @default.
• W2129186502 date "2004-09-01" @default.
• W2129186502 modified "2023-10-18" @default.
• W2129186502 title "Cyclooxygenase-2 inhibitor and cisplatin combination as a radiosensitizer in the treatment of head and neck cancer patients" @default.
• W2129186502 cites W1548467005 @default.
• W2129186502 cites W1913802169 @default.
• W2129186502 cites W1989022963 @default.
• W2129186502 cites W2010093588 @default.
• W2129186502 cites W2069871128 @default.
• W2129186502 cites W2120068217 @default.
• W2129186502 cites W2134947875 @default.
• W2129186502 cites W2135369121 @default.
• W2129186502 cites W2145078756 @default.
• W2129186502 cites W2154344774 @default.
• W2129186502 cites W2169053097 @default.
• W2129186502 cites W2408353708 @default.
• W2129186502 cites W2410849903 @default.
• W2129186502 doi "https://doi.org/10.1093/annonc/mdh360" @default.
• W2129186502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15319254" @default.
• W2129186502 hasPublicationYear "2004" @default.
• W2129186502 type Work @default.
• W2129186502 sameAs 2129186502 @default.
• W2129186502 citedByCount "2" @default.
• W2129186502 crossrefType "journal-article" @default.
• W2129186502 hasAuthorship W2129186502A5014590544 @default.
• W2129186502 hasAuthorship W2129186502A5039840531 @default.
• W2129186502 hasAuthorship W2129186502A5089639776 @default.
• W2129186502 hasAuthorship W2129186502A5090532877 @default.
• W2129186502 hasBestOaLocation W21291865021 @default.
• W2129186502 hasConcept C121608353 @default.
• W2129186502 hasConcept C126322002 @default.
• W2129186502 hasConcept C141071460 @default.
• W2129186502 hasConcept C143998085 @default.
• W2129186502 hasConcept C2776428644 @default.
• W2129186502 hasConcept C2776530083 @default.
• W2129186502 hasConcept C2776694085 @default.
• W2129186502 hasConcept C2776833033 @default.
• W2129186502 hasConcept C2778239845 @default.
• W2129186502 hasConcept C509974204 @default.
• W2129186502 hasConcept C58962609 @default.
• W2129186502 hasConcept C71924100 @default.
• W2129186502 hasConceptScore W2129186502C121608353 @default.
• W2129186502 hasConceptScore W2129186502C126322002 @default.
• W2129186502 hasConceptScore W2129186502C141071460 @default.
• W2129186502 hasConceptScore W2129186502C143998085 @default.
• W2129186502 hasConceptScore W2129186502C2776428644 @default.
• W2129186502 hasConceptScore W2129186502C2776530083 @default.
• W2129186502 hasConceptScore W2129186502C2776694085 @default.
• W2129186502 hasConceptScore W2129186502C2776833033 @default.
• W2129186502 hasConceptScore W2129186502C2778239845 @default.
• W2129186502 hasConceptScore W2129186502C509974204 @default.
• W2129186502 hasConceptScore W2129186502C58962609 @default.
• W2129186502 hasConceptScore W2129186502C71924100 @default.
• W2129186502 hasIssue "9" @default.
• W2129186502 hasLocation W21291865021 @default.
• W2129186502 hasLocation W21291865022 @default.
• W2129186502 hasOpenAccess W2129186502 @default.
• W2129186502 hasPrimaryLocation W21291865021 @default.
• W2129186502 hasRelatedWork W2005431320 @default.
• W2129186502 hasRelatedWork W2031183853 @default.
• W2129186502 hasRelatedWork W2071207166 @default.
• W2129186502 hasRelatedWork W2141904859 @default.
• W2129186502 hasRelatedWork W2161046978 @default.
• W2129186502 hasRelatedWork W2313027913 @default.
• W2129186502 hasRelatedWork W2329844376 @default.
• W2129186502 hasRelatedWork W2414041517 @default.
• W2129186502 hasRelatedWork W2460868461 @default.
• W2129186502 hasRelatedWork W3005553309 @default.
• W2129186502 hasVolume "15" @default.
• W2129186502 isParatext "false" @default.
• W2129186502 isRetracted "false" @default.
• W2129186502 magId "2129186502" @default.
• W2129186502 workType "article" @default.